- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01725308
A Study to Evaluate the Efficacy of FK949E in Bipolar Disorder Patients With Major Depressive Episodes
June 13, 2022 updated by: Astellas Pharma Inc
Phase II/III Study of FK949E: Placebo-controlled, Double-blind, Parallel-group Comparative Study and Open-label, Non-controlled Extension Study in Bipolar Disorder Patients With Major Depressive Episodes
In period I, the treatment effect of FK949E was compared with that of placebo in a blind manner in bipolar disorder patients with major depressive episodes.
In period II, the long-term safety and efficacy of FK949E was evaluated.
Study Overview
Detailed Description
This study consisted of two parts.
In Treatment Period I, FK949E or placebo was administered orally in a blind manner to bipolar disorder patients with major depressive episodes, with the aim of evaluating the superiority of FK949E over placebo and the dose response of two doses of FK949E based on changes in Montgomery-Asberg Depression Rating Scale (MADRS) total score.
In Treatment Period II, the long-term safety, efficacy and pharmacokinetics of open-label FK949E was evaluated in patients who completed Treatment Period I.
An analysis was performed for data in Treatment Period I and another analysis was done for data in combined Treatment Periods I and II.
Study Type
Interventional
Enrollment (Actual)
431
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Aichi, Japan
- Site JP00030
-
Aichi, Japan
- Site JP00031
-
Aichi, Japan
- Site JP00052
-
Aichi, Japan
- Site JP00055
-
Aichi, Japan
- Site JP00072
-
Aichi, Japan
- Site JP00092
-
Akita, Japan
- Site JP00003
-
Chiba, Japan
- Site JP00008
-
Chiba, Japan
- Site JP00009
-
Fukuoka, Japan
- Site JP00002
-
Fukuoka, Japan
- Site JP00037
-
Fukuoka, Japan
- Site JP00038
-
Fukuoka, Japan
- Site JP00039
-
Fukuoka, Japan
- Site JP00040
-
Fukuoka, Japan
- Site JP00041
-
Fukuoka, Japan
- Site JP00058
-
Fukuoka, Japan
- Site JP00082
-
Fukuoka, Japan
- Site JP00083
-
Fukuoka, Japan
- Site JP00091
-
Fukuoka, Japan
- Site JP00094
-
Fukuoka, Japan
- Site JP00095
-
Fukuoka, Japan
- Site JP00096
-
Fukuoka, Japan
- Site JP00097
-
Fukuoka, Japan
- Site JP00098
-
Fukushima, Japan
- Site JP00004
-
Gifu, Japan
- Site JP00028
-
Gunma, Japan
- Site JP00007
-
Gunma, Japan
- Site JP00006
-
Hiroshima, Japan
- Site JP00035
-
Hiroshima, Japan
- Site JP00056
-
Hiroshima, Japan
- Site JP00067
-
Hokkaido, Japan
- Site JP00001
-
Hokkaido, Japan
- Site JP00059
-
Hokkaido, Japan
- Site JP00061
-
Hokkaido, Japan
- Site JP00062
-
Hokkaido, Japan
- Site JP00068
-
Hokkaido, Japan
- Site JP00069
-
Hokkaido, Japan
- Site JP00073
-
Hokkaido, Japan
- Site JP00074
-
Hokkaido, Japan
- Site JP00076
-
Ibaraki, Japan
- Site JP00005
-
Kagawa, Japan
- Site JP00049
-
Kanagawa, Japan
- Site JP00021
-
Kanagawa, Japan
- Site JP00022
-
Kanagawa, Japan
- Site JP00023
-
Kanagawa, Japan
- Site JP00024
-
Kanagawa, Japan
- Site JP00025
-
Kumamoto, Japan
- Site JP00042
-
Kumamoto, Japan
- Site JP00050
-
Kyoto, Japan
- Site JP00032
-
Kyoto, Japan
- Site JP00084
-
Miyagi, Japan
- Site JP00077
-
Nagano, Japan
- Site JP00027
-
Nara, Japan
- Site JP00075
-
Oita, Japan
- Site JP00053
-
Okayama, Japan
- Site JP00054
-
Okayama, Japan
- Site JP00079
-
Okinawa, Japan
- Site JP00043
-
Okinawa, Japan
- Site JP00046
-
Osaka, Japan
- Site JP00033
-
Osaka, Japan
- Site JP00034
-
Osaka, Japan
- Site JP00047
-
Osaka, Japan
- Site JP00063
-
Shizuoka, Japan
- Site JP00029
-
Tokushima, Japan
- Site JP00036
-
Tokyo, Japan
- Site JP00011
-
Tokyo, Japan
- Site JP00012
-
Tokyo, Japan
- Site JP00014
-
Tokyo, Japan
- Site JP00010
-
Tokyo, Japan
- Site JP00013
-
Tokyo, Japan
- Site JP00015
-
Tokyo, Japan
- Site JP00016
-
Tokyo, Japan
- Site JP00017
-
Tokyo, Japan
- Site JP00018
-
Tokyo, Japan
- Site JP00019
-
Tokyo, Japan
- Site JP00020
-
Tokyo, Japan
- Site JP00045
-
Tokyo, Japan
- Site JP00048
-
Tokyo, Japan
- Site JP00051
-
Tokyo, Japan
- Site JP00057
-
Tokyo, Japan
- Site JP00060
-
Tokyo, Japan
- Site JP00064
-
Tokyo, Japan
- Site JP00065
-
Tokyo, Japan
- Site JP00066
-
Tokyo, Japan
- Site JP00070
-
Tokyo, Japan
- Site JP00071
-
Tokyo, Japan
- Site JP00078
-
Tokyo, Japan
- Site JP00081
-
Tokyo, Japan
- Site JP00085
-
Tokyo, Japan
- Site JP00086
-
Tokyo, Japan
- Site JP00087
-
Tokyo, Japan
- Site JP00088
-
Tokyo, Japan
- Site JP00089
-
Tokyo, Japan
- Site JP00090
-
Tokyo, Japan
- Site JP00093
-
Tokyo, Japan
- Site JP00099
-
Tottori, Japan
- Site JP00044
-
Toyama, Japan
- Site JP00026
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 64 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diagnosis of bipolar I or II disorder as specified in the Diagnostic and Statistical Manual of Mental Disorders Ver. 4 Text Revision (DSM-IV-TR,) with a major depressive episode
- The Hamilton Depression Rating Scale (HAM-D17) total score of 20 points or more and HAM-D17 depressed mood score of 2 points or more
- Able to participate in the study with understanding of and compliance with subject requirements during the study in the investigator's or subinvestigator's opinion
Exclusion Criteria:
- Concurrent or previous history of DSM-IV-TR Axis I disorders, except bipolar disorder, within the last 6 months before informed consent
- Concurrence of DSM-IV-TR Axis II disorder that is considered to greatly affect patient's current mental status
- The Young Mania Rating Scale (YMRS) total score of 13 points or more
- Nine or more mood episodes within the last 12 months before informed consent
- Lack of response to at least 6-week treatment with at least 2 antidepressants for the current major depressive episode in the investigator's or subinvestigator's opinion
- History of abuse or dependence of alcohol or substances other than caffeine and nicotine
- Treatment with a depot antipsychotic within the last 42 days before primary registration
- Unable to stop taking mood stabilizers (lithium carbonate and/or sodium valproate), lamotrigine, antipsychotics, or antidepressants from 7 days before secondary registration
- Unable to stop taking antiepileptics (except lamotrigine and sodium valproate), antianxiety agents, hypnotics, sedatives, psychostimulants, antiparkinsonian agents, cerebral ameliorators, antidementia agents, or anorectics, except those specified as conditionally-allowed concomitant drugs, after primary registration
- Electroconvulsive therapy within the last 76 days before primary registration
- The current major depressive episode persisting for more than 12 months or less than 4 weeks before informed consent
- A possible need of psychotherapy during the study period (unless the therapy has been commenced at least 76 days before primary registration and been maintained on a fixed level at fixed frequency)
- Documented or suspected conditions such as renal failure, hepatic failure, serious cardiac disease, hepatitis B, hepatitis C, or acquired immunodeficiency syndrome (AIDS) (or to be a carrier of hepatitis B, hepatitis C, or AIDS)
- Concurrence of malignancy or history of cured malignancy within 5 years
- Concurrence of uncontrolled hypertension (defined as a systolic blood pressure of 180 mmHg or more, or a diastolic blood pressure of 110 mmHg or more at primary registration) or unstable angina that may worsen with the study or may affect the study results based on the clinical judgment of the investigator or sub-investigator
- Concurrence of hypotension (defined as a systolic blood pressure of less than 100 mmHg at primary registration) or orthostatic hypotension
- History of transient, idiopathic orthostatic hypotension, with or without pre-syncope symptoms or syncope, or a current condition susceptible to transient hypotension, such as dehydration and decreased blood volume
- Concurrent or previous history of cerebrovascular disease or transient ischemic attack (TIA)
- Abnormal laboratory or electrocardiographic findings considered clinically significant in the investigator's or subinvestigator's opinion (in reference to grade 3 of the Adverse Drug Reactions Severity Grading Criteria [Notification No. 80 of the Safety Division, Pharmaceutical Affairs Bureau, Ministry of Health and Welfare dated 29 June 1992])
- Participation in another clinical study or post-marketing study within the last 12 weeks before informed consent
- History of quetiapine therapy during the current major depressive episode
- Pregnant or lactating women
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Participants who received placebo once daily at bedtime for 8 weeks in Treatment Period I and were evaluated against the transition criteria to transfer to Treatment Period II.
If transition criteria were not met, participants underwent to a dose-tapering period (1 week) and a follow-up period (1 week) thereafter.
If transition criteria were met, participants went into Treatment Period II.
|
Taken by mouth (orally).
|
Experimental: FK949E 150 mg
After 2 days of up-titration, participants who received FK949E 150 mg once daily at bedtime for 8 weeks in Treatment Period I and were evaluated against the transition criteria to transfer to Treatment Period II.
If transition criteria were not met, participants underwent to a dose-tapering period (1 week) and a follow-up period (1 week) thereafter.
If transition criteria were met, participants went into Treatment Period II.
|
Taken by mouth (orally).
Other Names:
|
Experimental: FK949E 300 mg
After 4 days of up-titration, participants who received FK949E 300 mg once daily at bedtime for 8 weeks in Treatment Period I and were evaluated against the transition criteria to transfer to Treatment Period II.
If transition criteria were not met, participants underwent to a dose-tapering period (1 week) and a follow-up period (1 week) thereafter.
If transition criteria were met, participants went into Treatment Period II.
|
Taken by mouth (orally).
Other Names:
|
Experimental: Placebo / FK949E
Participants received placebo administered orally once daily at bedtime for 8 weeks in Treatment Period I. Participants who met the transition criteria continued to Treatment Period II which consisted of a transition period in which participants continued to receive placebo for 4 weeks, followed by a 1-week dose adjustment period, and a treatment period in which participants received either open-label FK949E 150 mg or 300 mg (depending on dose increase or reduction guidelines) administered orally for 39 weeks.
Participants underwent a dose-tapering period (1 week) and a follow-up period (1 week) thereafter.
|
Taken by mouth (orally).
Taken by mouth (orally).
Other Names:
|
Experimental: FK949E 150 mg / FK949E
After 2 days of up-titration, participants received FK949E 150 mg administered orally once daily at bedtime for 8 weeks in Treatment Period I. Participants who met the transition criteria continued to Treatment Period II which consisted of a transition period in which participants continued to receive FK949E 150 mg for 4 weeks followed by a 1-week dose-adjustment period and a treatment period in which participants received either open-label FK949E 150 mg or 300 mg (depending on dose increase or reduction guidelines) administered orally for 39 weeks.
Participants underwent a dose-tapering period (1 week) and a follow-up period (1 week) thereafter.
|
Taken by mouth (orally).
Other Names:
|
Experimental: FK949E 300 mg / FK949E
After 4 days of up-titration, participants received FK949E 300 mg administered orally once daily at bedtime for 8 weeks in Treatment Period I. Participants who met the transition criteria continued to Treatment Period II which consisted of a transition period in which participants continued to receive FK949E 300 mg for 4 weeks followed by a 1-week dose-adjustment period and a treatment period in which participants received either open-label FK949E 150 mg or 300 mg (depending on dose increase or reduction guidelines) administered orally for 39 weeks.
Participants underwent a dose-tapering period (1 week) and a follow-up period (1 week) thereafter.
|
Taken by mouth (orally).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline to End of Treatment Period I in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
Time Frame: Baseline and Week 8
|
The MADRS is a 10-item scale to measure the severity of depressive episodes, where each item is rated on a scale from 0 to 6.
The MADRS total score ranges from 0 to 60 with lower scores indicating less depressive symptoms.
|
Baseline and Week 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in MADRS Total Score (Treatment Period I)
Time Frame: Baseline and Weeks 1, 2, 3, 4, 6, 8
|
The MADRS is a 10-item scale to measure the severity of depressive episodes, where each item is rated on a scale from 0 to 6.
The MADRS total score ranges from 0 to 60 with lower scores indicating less depressive symptoms.
|
Baseline and Weeks 1, 2, 3, 4, 6, 8
|
Change From Baseline in MADRS Total Score (Combined Treatment Period I and II)
Time Frame: Baseline (Week 0 for FK949E 150 mg/FK949E & FK949E 300 mg/FK949E and Week 12 for Placebo/FK949E) and Weeks 1, 2, 3, 4, 6, 8, 10, 12 13, 14, 16, 18, 20, 24, 28, 32, 36, 40, 44, 48, 52
|
The MADRS is a10-item scale to measure the severity of depressive episodes, where each item is rated on a scale from 0 to 6.
The MADRS total score ranges from 0 to 60 with lower scores indicating less depressive symptoms.
Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-12.
|
Baseline (Week 0 for FK949E 150 mg/FK949E & FK949E 300 mg/FK949E and Week 12 for Placebo/FK949E) and Weeks 1, 2, 3, 4, 6, 8, 10, 12 13, 14, 16, 18, 20, 24, 28, 32, 36, 40, 44, 48, 52
|
Number of Participants With MADRS Response (Treatment Period I)
Time Frame: Baseline and Weeks 1, 2, 3, 4, 6, 8
|
A MADRS response was defined as a decrease in MADRS total score of 50% or more from baseline.
The MADRS is a10-item scale to measure the severity of depressive episodes, where each item is rated on a scale from 0 to 6.
The MADRS total score ranges from 0 to 60 with lower scores indicating less depressive symptoms.
|
Baseline and Weeks 1, 2, 3, 4, 6, 8
|
Number of Participants With MADRS Response (Combined Treatment Period I and II)
Time Frame: Baseline (Week 0 for FK949E 150 mg/FK949E & FK949E 300 mg/FK949E and Week 12 for Placebo/FK949E) and Weeks 1, 2, 3, 4, 6, 8, 10, 12, 13, 14, 16, 18, 20, 24, 28, 32, 36, 40, 44, 48, 52
|
A MADRS response was defined as a decrease in MADRS total score of 50% or more from baseline.
The MADRS is a 10-item scale to measure the severity of depressive episodes, where each item is rated on a scale from 0 to 6.
The MADRS total score ranges from 0 to 60 with lower scores indicating less depressive symptoms.
Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-12.
|
Baseline (Week 0 for FK949E 150 mg/FK949E & FK949E 300 mg/FK949E and Week 12 for Placebo/FK949E) and Weeks 1, 2, 3, 4, 6, 8, 10, 12, 13, 14, 16, 18, 20, 24, 28, 32, 36, 40, 44, 48, 52
|
Number of Participants With MADRS Remission (Treatment Period I)
Time Frame: Weeks 1, 2, 3, 4, 6, 8
|
MADRS remission was defined as MADRS total score of 12 or less.
The MADRS is a 10-item scale to measure the severity of depressive episodes, where each item is rated on a scale from 0 to 6.
The MADRS total score ranges from 0 to 60 with lower scores indicating less depressive symptoms.
|
Weeks 1, 2, 3, 4, 6, 8
|
Number of Participants With MADRS Remission (Combined Treatment Period I and II)
Time Frame: Weeks 1, 2, 3, 4, 6, 8, 10, 12, 13, 14, 16, 18, 20, 24, 28, 32, 36, 40, 44, 48, 52
|
MADRS remission was defined as MADRS total score of 12 or less.
The MADRS is a 10-item scale to measure the severity of depressive episodes, where each item is rated on a scale from 0 to 6.
The MADRS total score ranges from 0 to 60 with lower scores indicating less depressive symptoms.
Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-10.
|
Weeks 1, 2, 3, 4, 6, 8, 10, 12, 13, 14, 16, 18, 20, 24, 28, 32, 36, 40, 44, 48, 52
|
Change From Baseline in Hamilton Depression Rating Scale (HAM-D17) Total Score (Treatment Period I)
Time Frame: Baseline and Weeks 1, 2, 3, 4, 6, 8
|
The HAM-D17 is a clinician-rated 17-item scale for assessing the severity of depression symptoms.
The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms.
The rating is based on the past 7 days prior to the time of assessment.
The total score ranges from 0 to 52, where a higher score indicates a greater depressive state.
|
Baseline and Weeks 1, 2, 3, 4, 6, 8
|
Change From Baseline in HAM-D17 (Combined Treatment Period I and II)
Time Frame: Baseline (Week 0 for FK949E 150 mg/FK949E & FK949E 300 mg/FK949E and Week 12 for Placebo/FK949E) and Weeks 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 20, 28, 36, 40, 44, 52
|
The HAM-D17 is a clinician-rated 17-item scale for assessing the severity of depression symptoms.
The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms.
The rating is based on the past 7 days prior to the time of assessment.
The total score ranges from 0 to 52, where a higher score indicates a greater depressive state.
Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-12.
|
Baseline (Week 0 for FK949E 150 mg/FK949E & FK949E 300 mg/FK949E and Week 12 for Placebo/FK949E) and Weeks 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 20, 28, 36, 40, 44, 52
|
Number of Participants With HAM-D17 Response (Treatment Period I)
Time Frame: Baseline and Weeks 1, 2, 3, 4, 6, 8
|
A HAM-D17 response was defined as a decrease in HAM-D17 total score of 50% or more from baseline.
The HAM-D17 is a clinician-rated 17-item scale for assessing the severity of depression symptoms.
The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms.
The rating is based on the past 7 days prior to the time of assessment.
The total score ranges from 0 to 52, where a higher score indicates a greater depressive state.
|
Baseline and Weeks 1, 2, 3, 4, 6, 8
|
Number of Participants With HAM-D17 Response (Combined Treatment Period I and II)
Time Frame: Baseline (Week 0 for FK949E 150 mg/FK949E & FK949E 300 mg/FK949E and Week 12 for Placebo/FK949E) and Weeks 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 20, 28, 36, 44, 52
|
A HAM-D17 response was defined as a decrease in HAM-D17 total score of 50% or more from baseline.
The HAM-D17 is a clinician-rated 17-item scale for assessing the severity of depression symptoms.
The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms.
The rating is based on the past 7 days prior to the time of assessment.
The total score ranges from 0 to 52, where a higher score indicates a greater depressive state.
Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-12.
|
Baseline (Week 0 for FK949E 150 mg/FK949E & FK949E 300 mg/FK949E and Week 12 for Placebo/FK949E) and Weeks 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 20, 28, 36, 44, 52
|
Change From Baseline in Clinical Global Impression-Bipolar Disorder-Severity (CGI-BP-S): Mania (Treatment Period I)
Time Frame: Baseline and Weeks 1, 2, 3, 4, 6, 8
|
The CGI-BP-S is a scale which assesses a participant's severity of their overall bipolar illness, depression, and mania as assessed by the clinician using a scale from 1 (not ill) to 7 (very severely ill).
|
Baseline and Weeks 1, 2, 3, 4, 6, 8
|
Change From Baseline in CGI-BP-S: Mania (Combined Treatment Period I and II)
Time Frame: Baseline (Week 0 for FK949E 150 mg/FK949E & FK949E 300 mg/FK949E and Week 12 for Placebo/FK949E) and Weeks 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, 44, 48, 52
|
The CGI-BP-S is a scale which assesses a participant's severity of their overall bipolar illness, depression, and mania as assessed by the clinician using a scale from 1 (not ill) to 7 (very severely ill).
Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-12.
|
Baseline (Week 0 for FK949E 150 mg/FK949E & FK949E 300 mg/FK949E and Week 12 for Placebo/FK949E) and Weeks 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, 44, 48, 52
|
Change From Baseline in CGI-BP-S: Depression (Treatment Period I)
Time Frame: Baseline and Weeks 1, 2, 3, 4, 6, 8
|
The CGI-BP-S is a scale which assesses a participant's severity of their overall bipolar illness, depression, and mania as assessed by the clinician with the scale from 1 (not ill) to 7 (very severely ill).
|
Baseline and Weeks 1, 2, 3, 4, 6, 8
|
Change From Baseline in CGI-BP-S: Depression (Combined Treatment Period I and II)
Time Frame: Baseline (Week 0 for FK949E 150 mg/FK949E & FK949E 300 mg/FK949E and Week 12 for Placebo/FK949E) and Weeks 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, 44, 48, 52
|
The CGI-BP-S is a scale which assesses a participant's severity of their overall bipolar illness, depression, and mania as assessed by the clinician using a scale from 1 (not ill) to 7 (very severely ill).
Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-12.
|
Baseline (Week 0 for FK949E 150 mg/FK949E & FK949E 300 mg/FK949E and Week 12 for Placebo/FK949E) and Weeks 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, 44, 48, 52
|
Change From Baseline in CGI-BP-S: Overall Bipolar Illness (Treatment Period I)
Time Frame: Baseline and Weeks 1, 2, 3, 4, 6, 8
|
The CGI-BP-S is a scale which assesses a participant's severity of their overall bipolar illness, depression, and mania as assessed by the clinician with the scale from 1 (not ill) to 7 (very severely ill).
|
Baseline and Weeks 1, 2, 3, 4, 6, 8
|
Change From Baseline in CGI-BP-S: Overall Bipolar Illness (Combined Treatment Period I and II)
Time Frame: Baseline (Week 0 for FK949E 150 mg/FK949E & FK949E 300 mg/FK949E and Week 12 for Placebo/FK949E) and Weeks 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, 44, 48, 52
|
The CGI-BP-S is a scale which assesses a participant's severity of their overall bipolar illness, depression, and mania as assessed by the clinician using a scale from 1 (not ill) to 7 (very severely ill).
Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-12.
|
Baseline (Week 0 for FK949E 150 mg/FK949E & FK949E 300 mg/FK949E and Week 12 for Placebo/FK949E) and Weeks 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, 44, 48, 52
|
Clinical Global Impression-Bipolar Disorder-Change (CGI-BP-C): Mania (Treatment Period I)
Time Frame: Weeks 1, 2, 3, 4, 6, 8
|
The CGI-BP-C is a scale which assesses the degree of change or improvement from baseline for each of overall bipolar illness, depression and mania, by grading it using 8 grades, from 1 (very much improved) to 7 (very much worse) or 8 (not applicable).
Grade 8 (not applicable) was regarded as a missing value for purposes of calculating the mean score.
|
Weeks 1, 2, 3, 4, 6, 8
|
CGI-BP-C: Mania (Combined Treatment Period I and II)
Time Frame: Weeks 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, 44, 48, 52 (Placebo/FK949E only from week 12, FK949E 150 mg/FK949E & FK949E 300 mg/FK949E from week 1)
|
The CGI-BP-C is a scale which assesses the degree of change or improvement from baseline for each of overall bipolar illness, depression and mania, by grading it using 8 grades, from 1 (very much improved) to 7 (very much worse) or 8 (not applicable).
Grade 8 (not applicable) was regarded as a missing value for purposes of calculating the mean score.
Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-10.
|
Weeks 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, 44, 48, 52 (Placebo/FK949E only from week 12, FK949E 150 mg/FK949E & FK949E 300 mg/FK949E from week 1)
|
CGI-BP-C: Depression (Treatment Period I)
Time Frame: Weeks 1, 2, 3, 4, 6, 8
|
The CGI-BP-C is a scale which assesses the degree of change or improvement from baseline for each of overall bipolar illness, depression and mania, by grading it using 8 grades, from 1 (very much improved) to 7 (very much worse) or 8 (not applicable).
Grade 8 (not applicable) was regarded as a missing value for purposes of calculating the mean score.
|
Weeks 1, 2, 3, 4, 6, 8
|
CGI-BP-C: Depression (Combined Treatment Period I and II)
Time Frame: Weeks 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, 44, 48, 52 (Placebo/FK949E only from week 12, FK949E 150 mg/FK949E & FK949E 300 mg/FK949E from week 1)
|
The CGI-BP-C is a scale which assesses the degree of change or improvement from baseline for each of overall bipolar illness, depression and mania, by grading it using 8 grades, from 1 (very much improved) to 7 (very much worse) or 8 (not applicable).
Grade 8 (not applicable) was regarded as a missing value for purposes of calculating the mean score.
Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-10.
|
Weeks 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, 44, 48, 52 (Placebo/FK949E only from week 12, FK949E 150 mg/FK949E & FK949E 300 mg/FK949E from week 1)
|
CGI-BP-C: Overall Bipolar Illness (Treatment Period I)
Time Frame: Weeks 1, 2, 3, 4, 6, 8
|
The CGI-BP-C is a scale which assesses the degree of change or improvement from baseline for each of overall bipolar illness, depression and mania, by grading it using 8 grades, from 1 (very much improved) to 7 (very much worse) or 8 (not applicable).
Grade 8 (not applicable) was regarded as a missing value for purposes of calculating the mean score.
|
Weeks 1, 2, 3, 4, 6, 8
|
CGI-BP-C: Overall Bipolar Illness (Combined Treatment Period I and II)
Time Frame: Weeks 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, 44, 48, 52 (Placebo/FK949E only from week 12, FK949E 150 mg/FK949E & FK949E 300 mg/FK949E from week 1)
|
The CGI-BP-C is a scale which assesses the degree of change or improvement from baseline for each of overall bipolar illness, depression and mania, by grading it using 8 grades, from 1 (very much improved) to 7 (very much worse) or 8 (not applicable).
Grade 8 (not applicable) was regarded as a missing value for purposes of calculating the mean score.
Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-10.
|
Weeks 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, 44, 48, 52 (Placebo/FK949E only from week 12, FK949E 150 mg/FK949E & FK949E 300 mg/FK949E from week 1)
|
Number of Participants With Adverse Events (Treatment Period I)
Time Frame: Up to 8 weeks
|
An adverse event (AE) is defined as any undesirable or unintended sign (including abnormal laboratory test values), symptom, or disease occurring while the study drug was administered, regardless of whether or not there was a causal relationship with the study drug.
A serious AE is defined as a an event resulting in death, persistent or significant disability/incapacity or congenital anomaly or birth defect, was life-threatening, required or prolonged hospitalization or was considered medically important.
|
Up to 8 weeks
|
Number of Participants With Adverse Events (Combined Treatment Period I and II)
Time Frame: Up to 54 weeks (Placebo / FK949E, from week 12 to week 52, for FK949E 150 mg / FK949E & FK949E 300 mg / FK949E groups, from week 0 to week 52)
|
An AE is defined as any undesirable or unintended sign (including abnormal laboratory test values), symptom, or disease occurring while the study drug was administered, regardless of whether or not there was a causal relationship with the study drug.
A serious AE is defined as a an event resulting in death, persistent or significant disability/incapacity or congenital anomaly or birth defect, was life-threatening, required or prolonged hospitalization or was considered medically important.
AEs reported are AEs that occurred after the start of the FK949E treatment for all groups.
|
Up to 54 weeks (Placebo / FK949E, from week 12 to week 52, for FK949E 150 mg / FK949E & FK949E 300 mg / FK949E groups, from week 0 to week 52)
|
Change From Baseline in Drug Induced Extra-Pyramidal Symptoms Scale (DIEPSS): Total Score (Treatment Period I)
Time Frame: Baseline and Weeks 4, 8
|
The DIEPSS is a scale used to evaluate drug-induced extrapyramidal symptoms.
DIEPSS is composed of 8 individual symptom parameters and a global assessment of severity, each rated on a 5-point scale, with lower scores indicating as "normal."
The DIEPSS total score ranges from 0 (none, normal) to 32 (severe), and excludes the global assessment of severity.
|
Baseline and Weeks 4, 8
|
Change From Baseline in DIEPSS: Total Score (Combined Treatment Period I and II)
Time Frame: Baseline (Week 0 for FK949E 150 mg/FK949E & FK949E 300 mg/FK949E and Week 12 for Placebo/FK949E) and Weeks 4, 8, 12, 16, 20, 28, 36, 44, 52
|
The DIEPSS is a scale used to evaluate drug-induced extrapyramidal symptoms.
DIEPSS is composed of 8 individual symptom parameters and a global assessment of severity, each rated on a 5-point scale, with lower scores indicating as "normal."
The DIEPSS total score ranges from 0 (none, normal) to 32 (severe), and excludes the global assessment of severity.
Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-12.
|
Baseline (Week 0 for FK949E 150 mg/FK949E & FK949E 300 mg/FK949E and Week 12 for Placebo/FK949E) and Weeks 4, 8, 12, 16, 20, 28, 36, 44, 52
|
Change From Baseline in DIEPSS: Parkinsonism (Treatment Period I)
Time Frame: Baseline and Weeks 4, 8
|
The DIEPSS is a scale used to evaluate drug-induced extrapyramidal symptoms.
DIEPSS is composed of 8 individual symptom parameters and a global assessment of severity, each rated on a 5-point scale, with lower scores indicating as "normal."
Parkinsonism is a total of the gait disturbance, bradykinesia, salivation, muscle rigidity, and tremor scores and ranges from 0 (none, normal) to 20 (severe).
|
Baseline and Weeks 4, 8
|
Change From Baseline in DIEPSS: Parkinsonism (Combined Treatment Period I and II)
Time Frame: Baseline (Week 0 for FK949E 150 mg/FK949E & FK949E 300 mg/FK949E and Week 12 for Placebo/FK949E) and Weeks 4, 8, 12, 16, 20, 28, 36, 44, 52
|
The DIEPSS is a scale used to evaluate drug-induced extrapyramidal symptoms.
DIEPSS is composed of 8 individual symptom parameters and a global assessment of severity, each rated on a 5-point scale, with lower scores indicating as "normal."
Parkinsonism is a total of the gait disturbance, bradykinesia, salivation, muscle rigidity, and tremor scores and ranges from 0 (none, normal) to 20 (severe).
Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-12.
|
Baseline (Week 0 for FK949E 150 mg/FK949E & FK949E 300 mg/FK949E and Week 12 for Placebo/FK949E) and Weeks 4, 8, 12, 16, 20, 28, 36, 44, 52
|
Change From Baseline in Young Mania Rating Scale (YMRS) (Treatment Period I)
Time Frame: Baseline and Weeks 1, 2, 3, 4, 6, 8
|
The YMRS is a scale used to evaluate manic symptoms.
The YMRS total score was the total assessment of assessed points for 11 items, ranges from 0 to 60 (each item is scored from either 0-4 or 0-8 by severity (0 = absent and 4/8 = displays mood/behavior to a greater degree).
A lower score indicates "Absent" or "Normal."
|
Baseline and Weeks 1, 2, 3, 4, 6, 8
|
Change From Baseline in YMRS (Combined Treatment Period I and II)
Time Frame: Baseline (Week 0 for FK949E 150 mg/FK949E & FK949E 300 mg/FK949E and Week 12 for Placebo/FK949E) and Weeks 1, 2, 3, 4, 6, 8, 10, 12, 13, 14, 16, 18, 20, 24, 28, 32, 36, 40, 44, 48, 52
|
The YMRS is a scale used to evaluate manic symptoms.
The YMRS total score was the total assessment of assessed points for 11 items, ranges from 0 to 60 (each item is scored from either 0-4 or 0-8 by severity (0 = absent and 4/8 = displays mood/behavior to a greater degree).
A lower score indicates "Absent" or "Normal."
Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-12.
|
Baseline (Week 0 for FK949E 150 mg/FK949E & FK949E 300 mg/FK949E and Week 12 for Placebo/FK949E) and Weeks 1, 2, 3, 4, 6, 8, 10, 12, 13, 14, 16, 18, 20, 24, 28, 32, 36, 40, 44, 48, 52
|
Number of Participants With an Affirmative Response to Columbia Suicide Severity Rating Scale (C-SSRS): Suicidal Ideation (Treatment Period I)
Time Frame: Weeks 4, 8
|
The C-SSRS is a scale for assessing risk for suicidal behavior and suicide ideation and was administered by the clinician.
Affirmative or negative responses were provided to 5 items for suicide ideation (1.
Wish to be dead; 2. Suicidal thoughts; 3. Suicidal thoughts with a method (no specific plan or intent to act); 4. Suicidal intent (without a specific plan); 5. Suicidal intent with specific plan.
If participants responded with a negative response for questions 1 and 2, the remaining questions are skipped.
If question 2 was responded to with a positive response, the remaining questions need to be asked.
|
Weeks 4, 8
|
Number of Participants With an Affirmative Response to C-SSRS: Suicidal Ideation - Wish to be Dead (Combined Treatment Period I and II)
Time Frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 (Placebo/FK949E only from week 12, FK949E 150 mg/FK949E & FK949E 300 mg/FK949E from week 4)
|
The C-SSRS is a scale for assessing risk for suicidal behavior and suicide ideation and was administered by the clinician.
Affirmative or negative responses were provided to 5 items for suicide ideation (1.
Wish to be dead; 2. Suicidal thoughts; 3. Suicidal thoughts with a method (no specific plan or intent to act); 4. Suicidal intent (without a specific plan); 5. Suicidal intent with specific plan.
If participants responded with a negative response for questions 1 and 2, the remaining questions are skipped.
If question 2 was responded to with a positive response, the remaining questions need to be asked.
Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-10.
|
Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 (Placebo/FK949E only from week 12, FK949E 150 mg/FK949E & FK949E 300 mg/FK949E from week 4)
|
Number of Participants With an Affirmative Response to C-SSRS: Suicidal Ideation - Suicidal Thoughts (Combined Treatment Period I and II)
Time Frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 (Placebo/FK949E only from week 12, FK949E 150 mg/FK949E & FK949E 300 mg/FK949E from week 4)
|
The C-SSRS is a scale for assessing risk for suicidal behavior and suicide ideation and was administered by the clinician.
Affirmative or negative responses were provided to 5 items for suicide ideation (1.
Wish to be dead; 2. Suicidal thoughts; 3. Suicidal thoughts with a method (no specific plan or intent to act); 4. Suicidal intent (without a specific plan); 5. Suicidal intent with specific plan.
If participants responded with a negative response for questions 1 and 2, the remaining questions are skipped.
If question 2 was responded to with a positive response, the remaining questions need to be asked.
Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-10.
|
Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 (Placebo/FK949E only from week 12, FK949E 150 mg/FK949E & FK949E 300 mg/FK949E from week 4)
|
Number of Participants With an Affirmative Response to C-SSRS: Suicidal Ideation - Suicidal Thoughts With Method (Combined Treatment Period I and II)
Time Frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 (Placebo/FK949E only from week 12, FK949E 150 mg/FK949E & FK949E 300 mg/FK949E from week 4)
|
The C-SSRS is a scale for assessing risk for suicidal behavior and suicide ideation and was administered by the clinician.
Affirmative or negative responses were provided to 5 items for suicide ideation (1.
Wish to be dead; 2. Suicidal thoughts; 3. Suicidal thoughts with a method (no specific plan or intent to act); 4. Suicidal intent (without a specific plan); 5. Suicidal intent with specific plan.
If participants responded with a negative response for questions 1 and 2, the remaining questions are skipped.
If question 2 was responded to with a positive response, the remaining questions need to be asked.
Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-10.
|
Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 (Placebo/FK949E only from week 12, FK949E 150 mg/FK949E & FK949E 300 mg/FK949E from week 4)
|
Number of Participants With an Affirmative Response to C-SSRS: Suicidal Ideation - Suicidal Intent Without a Plan (Combined Treatment Period I and II)
Time Frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 (Placebo/FK949E only from week 12, FK949E 150 mg/FK949E & FK949E 300 mg/FK949E from week 4)
|
The C-SSRS is a scale for assessing risk for suicidal behavior and suicide ideation and was administered by the clinician.
Affirmative or negative responses were provided to 5 items for suicide ideation (1.
Wish to be dead; 2. Suicidal thoughts; 3. Suicidal thoughts with a method (no specific plan or intent to act); 4. Suicidal intent (without a specific plan); 5. Suicidal intent with specific plan.
If participants responded with a negative response for questions 1 and 2, the remaining questions are skipped.
If question 2 was responded to with a positive response, the remaining questions need to be asked.
Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-10.
|
Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 (Placebo/FK949E only from week 12, FK949E 150 mg/FK949E & FK949E 300 mg/FK949E from week 4)
|
Number of Participants With an Affirmative Response to C-SSRS: Suicidal Ideation - Suicidal Intent With a Plan (Combined Treatment Period I and II)
Time Frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 (Placebo/FK949E only from week 12, FK949E 150 mg/FK949E & FK949E 300 mg/FK949E from week 4)
|
The C-SSRS is a scale for assessing risk for suicidal behavior and suicide ideation and was administered by the clinician.
Affirmative or negative responses were provided to 5 items for suicide ideation (1.
Wish to be dead; 2. Suicidal thoughts; 3. Suicidal thoughts with a method (no specific plan or intent to act); 4. Suicidal intent (without a specific plan); 5. Suicidal intent with specific plan.
If participants responded with a negative response for questions 1 and 2, the remaining questions are skipped.
If question 2 was responded to with a positive response, the remaining questions need to be asked.
Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-10.
|
Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 (Placebo/FK949E only from week 12, FK949E 150 mg/FK949E & FK949E 300 mg/FK949E from week 4)
|
Number of Participants With an Affirmative Response to C-SSRS: Suicidal Behaviors (Treatment Period I)
Time Frame: Weeks 4, 8
|
The C-SSRS is a scale for assessing risk for suicidal behavior and suicide ideation and was administered by the clinician.
Affirmative or negative responses were provided to 7 items to suicidal behaviors (1.
suicide attempt; 2. Self-injury without suicide intent; 3. discontinued suicide attempt; 4. interrupted suicide attempt; 5. preliminary action to suicide; 6. suicidal behavior; 7. completed suicide).
|
Weeks 4, 8
|
Number of Participants With an Affirmative Response to C-SSRS: Suicidal Behaviors - Suicide Attempt (Combined Treatment Period I and II)
Time Frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 (Placebo/FK949E only from week 12, FK949E 150 mg/FK949E & FK949E 300 mg/FK949E from week 4)
|
The C-SSRS is a scale for assessing risk for suicidal behavior and suicide ideation and was administered by the clinician.
Affirmative or negative responses were provided to 7 items to suicidal behaviors (1.
suicide attempt; 2. Self-injury without suicide intent; 3. discontinued suicide attempt; 4. interrupted suicide attempt; 5. preliminary action to suicide; 6. suicidal behavior; 7. completed suicide).
Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-10.
|
Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 (Placebo/FK949E only from week 12, FK949E 150 mg/FK949E & FK949E 300 mg/FK949E from week 4)
|
Number of Participants With an Affirmative Response to C-SSRS: Suicidal Behaviors - Self-injury Behavior Without Intent (Combined Treatment Period I and II)
Time Frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 (Placebo/FK949E only from week 12, FK949E 150 mg/FK949E & FK949E 300 mg/FK949E from week 4)
|
The C-SSRS is a scale for assessing risk for suicidal behavior and suicide ideation and was administered by the clinician.
Affirmative or negative responses were provided to 7 items to suicidal behaviors (1.
suicide attempt; 2. Self-injury without suicide intent; 3. discontinued suicide attempt; 4. interrupted suicide attempt; 5. preliminary action to suicide; 6. suicidal behavior; 7. completed suicide).
Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-10.
|
Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 (Placebo/FK949E only from week 12, FK949E 150 mg/FK949E & FK949E 300 mg/FK949E from week 4)
|
Number of Participants With an Affirmative Response to C-SSRS: Suicidal Behaviors - Discontinued Attempt (Combined Treatment Period I and II)
Time Frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 (Placebo/FK949E only from week 12, FK949E 150 mg/FK949E & FK949E 300 mg/FK949E from week 4)
|
The C-SSRS is a scale for assessing risk for suicidal behavior and suicide ideation and was administered by the clinician.
Affirmative or negative responses were provided to 7 items to suicidal behaviors (1.
suicide attempt; 2. Self-injury without suicide intent; 3. discontinued suicide attempt; 4. interrupted suicide attempt; 5. preliminary action to suicide; 6. suicidal behavior; 7. completed suicide).
Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-10.
|
Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 (Placebo/FK949E only from week 12, FK949E 150 mg/FK949E & FK949E 300 mg/FK949E from week 4)
|
Number of Participants With an Affirmative Response to C-SSRS: Suicidal Behaviors - Interrupted Attempt (Combined Treatment Period I and II)
Time Frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 (Placebo/FK949E only from week 12, FK949E 150 mg/FK949E & FK949E 300 mg/FK949E from week 4)
|
The C-SSRS is a scale for assessing risk for suicidal behavior and suicide ideation and was administered by the clinician.
Affirmative or negative responses were provided to 7 items to suicidal behaviors (1.
suicide attempt; 2. Self-injury without suicide intent; 3. discontinued suicide attempt; 4. interrupted suicide attempt; 5. preliminary action to suicide; 6. suicidal behavior; 7. completed suicide).
Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-10.
|
Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 (Placebo/FK949E only from week 12, FK949E 150 mg/FK949E & FK949E 300 mg/FK949E from week 4)
|
Number of Participants With an Affirmative Response to C-SSRS: Suicidal Behaviors - Preliminary Act to Suicide (Combined Treatment Period I and II
Time Frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 (Placebo/FK949E only from week 12, FK949E 150 mg/FK949E & FK949E 300 mg/FK949E from week 4)
|
The C-SSRS is a scale for assessing risk for suicidal behavior and suicide ideation and was administered by the clinician.
Affirmative or negative responses were provided to 7 items to suicidal behaviors (1.
suicide attempt; 2. Self-injury without suicide intent; 3. discontinued suicide attempt; 4. interrupted suicide attempt; 5. preliminary action to suicide; 6. suicidal behavior; 7. completed suicide).
Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-10.
|
Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 (Placebo/FK949E only from week 12, FK949E 150 mg/FK949E & FK949E 300 mg/FK949E from week 4)
|
Number of Participants With an Affirmative Response to C-SSRS: Suicidal Behaviors - Suicidal Behavior (Combined Treatment Period I and II)
Time Frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 (Placebo/FK949E only from week 12, FK949E 150 mg/FK949E & FK949E 300 mg/FK949E from week 4)
|
The C-SSRS is a scale for assessing risk for suicidal behavior and suicide ideation and was administered by the clinician.
Affirmative or negative responses were provided to 7 items to suicidal behaviors (1.
suicide attempt; 2. Self-injury without suicide intent; 3. discontinued suicide attempt; 4. interrupted suicide attempt; 5. preliminary action to suicide; 6. suicidal behavior; 7. completed suicide).
Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-10
|
Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 (Placebo/FK949E only from week 12, FK949E 150 mg/FK949E & FK949E 300 mg/FK949E from week 4)
|
Number of Participants With an Affirmative Response to C-SSRS: Suicidal Behaviors - Completed Suicide (Combined Treatment Period I and II)
Time Frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 (Placebo/FK949E only from week 12, FK949E 150 mg/FK949E & FK949E 300 mg/FK949E from week 4)
|
The C-SSRS is a scale for assessing risk for suicidal behavior and suicide ideation and was administered by the clinician.
Affirmative or negative responses were provided to 7 items to suicidal behaviors (1.
suicide attempt; 2. Self-injury without suicide intent; 3. discontinued suicide attempt; 4. interrupted suicide attempt; 5. preliminary action to suicide; 6. suicidal behavior; 7. completed suicide).
Baseline for Placebo / FK949E was at week 12 therefore no data were calculated for weeks 1-10.
|
Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 (Placebo/FK949E only from week 12, FK949E 150 mg/FK949E & FK949E 300 mg/FK949E from week 4)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Fukushi R, Nomura Y, Katashima M, Komatsu K, Sato Y, Takada A. Approach to Evaluating QT Prolongation of Quetiapine Fumarate in Late Stage of Clinical Development Using Concentration-QTc Modeling and Simulation in Japanese Patients With Bipolar Disorder. Clin Ther. 2020 Aug;42(8):1483-1493.e1. doi: 10.1016/j.clinthera.2020.06.002. Epub 2020 Aug 11.
- Fukushi R, Nomura Y, Katashima M, Komatsu K, Sato Y, Takada A. Population Pharmacokinetics Analysis of Quetiapine Extended-release Formulation in Japanese Patients with Bipolar Depression. Clin Ther. 2020 Jun;42(6):1067-1076.e2. doi: 10.1016/j.clinthera.2020.04.006. Epub 2020 Jun 6.
- Kanba S, Murasaki M, Koyama T, Takeuchi M, Shimizu Y, Arita E, Kuroishi K, Takeuchi M, Kamei S. Long-term mood/antidepressant effects of quetiapine extended-release formulation: an open-label, non-controlled extension study in Japanese patients with bipolar depression. BMC Psychiatry. 2019 Jun 26;19(1):198. doi: 10.1186/s12888-019-2181-9.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 7, 2012
Primary Completion (Actual)
August 1, 2015
Study Completion (Actual)
July 11, 2016
Study Registration Dates
First Submitted
November 8, 2012
First Submitted That Met QC Criteria
November 9, 2012
First Posted (Estimate)
November 12, 2012
Study Record Updates
Last Update Posted (Actual)
July 6, 2022
Last Update Submitted That Met QC Criteria
June 13, 2022
Last Verified
June 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 6949-CL-0021
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
IPD Plan Description
Access to anonymized individual participant level data will not be provided for this trial as it meets one or more of the exceptions described on www.clinicalstudydatarequest.com under "Sponsor Specific Details for Astellas."
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bipolar Disorder
-
ProgenaBiomeRecruitingBipolar Disorder | Bipolar I Disorder | Bipolar II Disorder | Bipolar Type I Disorder | Bipolar Disorder Mild | Bipolar Disorder Moderate | Bipolar Disorder SevereUnited States
-
Rush University Medical CenterThe Ryan Licht Sang Bipolar FoundationCompletedBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar Disorder I | Bipolar Affective DisorderUnited States
-
University of PittsburghNational Alliance for Research on Schizophrenia and DepressionCompletedBipolar I Disorder | Bipolar II Disorder | Bipolar Disorder NOSUnited States
-
Region StockholmKarolinska InstitutetRecruitingBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar II Disorder | Bipolar Affective Disorder; Remission in | Bipolar Affective Disorder, Currently Depressed, ModerateSweden
-
Hospital de Clinicas de Porto AlegreFederal University of Rio Grande do Sul; Hospital Moinhos de VentoActive, not recruitingBipolar Disorder | Bipolar Depression | Major Depressive Disorder | Bipolar I Disorder | Affective Disorder | Bipolar II DisorderBrazil
-
Medical University of South CarolinaMilken InstituteCompletedBipolar Disorder | Bipolar I Disorder | Bipolar II DisorderUnited States
-
Mayo ClinicCompletedMajor Depressive Disorder, Bipolar I and Bipolar IIUnited States
-
Joshua RosenblatRecruitingBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar II DisorderCanada
-
Myriad Genetic Laboratories, Inc.University of MinnesotaCompletedMajor Depressive Disorder, Bipolar I and Bipolar IIUnited States
-
Centre for Addiction and Mental HealthUniversity Health Network, TorontoNot yet recruitingBipolar Disorder | Bipolar Depression | Treatment- Resistant Bipolar Disorder | Type 2 Bipolar DisorderCanada
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States